These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 36747965)
1. Corrigendum to 'Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial'. von Rotz R; Schindowski EM; Jungwirth J; Schuldt A; Rieser NM; Zahoranszky K; Seifritz E; Nowak A; Nowak P; Jäncke L; Preller KH; Vollenweider FX EClinicalMedicine; 2023 Feb; 56():101841. PubMed ID: 36747965 [TBL] [Abstract][Full Text] [Related]
2. Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. von Rotz R; Schindowski EM; Jungwirth J; Schuldt A; Rieser NM; Zahoranszky K; Seifritz E; Nowak A; Nowak P; Jäncke L; Preller KH; Vollenweider FX EClinicalMedicine; 2023 Feb; 56():101809. PubMed ID: 36636296 [TBL] [Abstract][Full Text] [Related]
3. Corrigendum to "Effects of adding L-arginine orally to standard therapy in patients with COVID-19: A randomized, double-blind, placebo-controlled, parallel-group trial. Results of the first interim analysis.". Fiorentino G; Coppola A; Izzo R; Annunziata A; Bernardo M; Lombardi A; Trimarco V; Santulli G; Trimarco B EClinicalMedicine; 2022 Sep; 51():101636. PubMed ID: 36120704 [TBL] [Abstract][Full Text] [Related]
4. Corrigendum to "Nitazoxanide superiority to placebo to treat moderate COVID-19 - A Pilot prove of concept randomized double-blind clinical trial." [EClinicalMedicine 37 (2021) 100981]. Blum VF; Cimerman S; Hunter JR; Tierno P; Lacerda A; Soeiro A; Cardoso F; Bellei NC; Maricato J; Mantovani N; Vassao M; Dias D; Galinskas J; Janini LMR; Santos-Oliveira JR; Da-Cruz AM; Diaz RS EClinicalMedicine; 2021 Nov; 41():101203. PubMed ID: 34805808 [TBL] [Abstract][Full Text] [Related]
5. The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation. Rucker JJ; Marwood L; Ajantaival RJ; Bird C; Eriksson H; Harrison J; Lennard-Jones M; Mistry S; Saldarini F; Stansfield S; Tai SJ; Williams S; Weston N; Malievskaia E; Young AH J Psychopharmacol; 2022 Jan; 36(1):114-125. PubMed ID: 35090363 [TBL] [Abstract][Full Text] [Related]
6. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. Bogenschutz MP; Ross S; Bhatt S; Baron T; Forcehimes AA; Laska E; Mennenga SE; O'Donnell K; Owens LT; Podrebarac S; Rotrosen J; Tonigan JS; Worth L JAMA Psychiatry; 2022 Oct; 79(10):953-962. PubMed ID: 36001306 [TBL] [Abstract][Full Text] [Related]
7. Corrigendum to A randomised, double-blind, placebo-controlled clinical trial found that a novel herbal formula UROX® BEDTIME BUDDY assisted children for the treatment of nocturnal enuresis. Phytomedicine (2021) 153783 https://doi.org/10.1016/j.phymed.2021.153783. Schloss J; Ryan K; Steel A Phytomedicine; 2022 May; 99():153992. PubMed ID: 35217436 [No Abstract] [Full Text] [Related]
8. Corrigendum to "Safety of integrated mass drug administration of azithromycin, albendazole and ivermectin versus standard treatment regimens: a cluster-randomised trial in Ethiopia". McPherson S; Tafese G; Tafese T; Behaksra SW; Solomon H; Oljira B; Miecha H; Debebe KA; Kebede B; Gebre T; Kebede F; Seife F; Tadesse F; Mammo B; Aseffa A; Solomon AW; Mabey DCW; Marks M; Gadisa E EClinicalMedicine; 2023 Aug; 62():102120. PubMed ID: 37533412 [TBL] [Abstract][Full Text] [Related]
9. Corrigendum to "Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis" [EClinicalMedicine 55 (2022) 101795]. Fu Z; Liu J; Li S; Shi C; Zhang Y EClinicalMedicine; 2023 Apr; 58():101908. PubMed ID: 36969339 [TBL] [Abstract][Full Text] [Related]
10. Corrigendum to Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial [EClinicalMedicine 37 (2021) 100,959]". Krolewiecki A; Lifschitz A; Moragas M; Travacio M; Valentini R; Alonso DF; Solari R; Tinelli MA; Cimino RO; Álvarez L; Fleitas PE; Ceballos L; Golemba M; Fernández F; de Oliveira DF; Astudillo G; Baeck I; Farina J; Cardama GA; Mangano A; Spitzer E; Gold S; Lanusse C EClinicalMedicine; 2021 Sep; 39():101119. PubMed ID: 34462733 [TBL] [Abstract][Full Text] [Related]
11. Corrigendum to 'Lysophosphatidylcholine-Rich Nutrition Therapy Increased Gut Absorption of Coingested Dietary Fat: a Randomized Controlled Trial' [Curr Dev Nutr. 2023 Sep; 7(9): 101985]. Tindall A; Mascarenhas M; Maqbool A; Stallings VA Curr Dev Nutr; 2023 Nov; 7(11):102030. PubMed ID: 38116520 [TBL] [Abstract][Full Text] [Related]
12. Corrigendum to 'A comparison of electronically-delivered and face to face cognitive behavioural therapies in depressive disorders: A systematic review and meta-analysis' [EClinicalMedicine 24 (2020) 100442]. Sanger N; Samaan Z; Thabane L EClinicalMedicine; 2021 Nov; 41():101182. PubMed ID: 34825150 [TBL] [Abstract][Full Text] [Related]
13. Increased global integration in the brain after psilocybin therapy for depression. Daws RE; Timmermann C; Giribaldi B; Sexton JD; Wall MB; Erritzoe D; Roseman L; Nutt D; Carhart-Harris R Nat Med; 2022 Apr; 28(4):844-851. PubMed ID: 35411074 [TBL] [Abstract][Full Text] [Related]
14. Corrigendum to "Do children with disabilities have the same opportunities to play as children without disabilities? Evidence from the multiple indicator cluster surveys in 38 low and middle-income countries" [ECLINM 67 (2023) 102361]. Smythe T; Chen S; Rotenberg S; Unger M; Miner E; Seghers F; Servili C; Kuper H EClinicalMedicine; 2024 Jul; 73():102686. PubMed ID: 38993996 [TBL] [Abstract][Full Text] [Related]
15. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Holze F; Ley L; Müller F; Becker AM; Straumann I; Vizeli P; Kuehne SS; Roder MA; Duthaler U; Kolaczynska KE; Varghese N; Eckert A; Liechti ME Neuropsychopharmacology; 2022 May; 47(6):1180-1187. PubMed ID: 35217796 [TBL] [Abstract][Full Text] [Related]
16. Corrigendum to "Pranic Healing as a Complementary Therapy in Diabetic Foot Ulcer Management: A Randomised, Controlled, Double-Blind Trial". Glob Adv Integr Med Health; 2024; 13():27536130241228055. PubMed ID: 39291236 [TBL] [Abstract][Full Text] [Related]
17. Corrigendum to "EEG revealed improved vigilance regulation after stress exposure under Nx4 - A randomized, placebo-controlled, double-blind, cross-over trial" [IBRO Neurosci. Rep. 11C (2021) 175-182]. Chand T; Alizadeh S; Jamalabadi H; Herrmann L; Krylova M; Surova G; van der Meer J; Wagner G; Engert V; Walter M IBRO Neurosci Rep; 2022 Jun; 12():81. PubMed ID: 35028639 [TBL] [Abstract][Full Text] [Related]
18. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Carhart-Harris RL; Bolstridge M; Day CMJ; Rucker J; Watts R; Erritzoe DE; Kaelen M; Giribaldi B; Bloomfield M; Pilling S; Rickard JA; Forbes B; Feilding A; Taylor D; Curran HV; Nutt DJ Psychopharmacology (Berl); 2018 Feb; 235(2):399-408. PubMed ID: 29119217 [TBL] [Abstract][Full Text] [Related]
19. Corrigendum: A Chinese medicine formula (kunbixiao granule) for female rheumatoid arthritis: Study protocol for a double-blind, randomized, placebo-controlled trial. Wan Y; Yang J; Ma T; Wang W; Wang H; Sun W; Ye W; Yang L; Kou Q Front Pharmacol; 2022; 13():1074679. PubMed ID: 36408226 [TBL] [Abstract][Full Text] [Related]
20. Trial of Psilocybin versus Escitalopram for Depression. Carhart-Harris R; Giribaldi B; Watts R; Baker-Jones M; Murphy-Beiner A; Murphy R; Martell J; Blemings A; Erritzoe D; Nutt DJ N Engl J Med; 2021 Apr; 384(15):1402-1411. PubMed ID: 33852780 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]